This is an investigational study. Alpelisib is not FDA approved or commercially available. It is currently being used for research purposes only. Enzalutamide is FDA approved and commercially available for the treatment of metastatic, castrate-resistant prostate cancer. It is considered investigational to use alpelisib and enzalutamide to treat metastatic breast cancer.